Compare · ACN vs PHR
ACN vs PHR
Side-by-side comparison of Accenture plc (ACN) and Phreesia Inc. (PHR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACN and PHR operate in Real Estate (Real Estate), so they compete in similar markets.
- ACN is the larger of the two at $116.02B, about 201.0x PHR ($577.3M).
- Over the past year, ACN is down 44.9% and PHR is down 66.1% - ACN leads by 21.2 points.
- ACN has been more active in the news (35 items in the past 4 weeks vs 6 for PHR).
- Both have 25 recent analyst ratings on file.
- Company
- Accenture plc
- Phreesia Inc.
- Price
- $174.44-2.16%
- $9.32-2.15%
- Market cap
- $116.02B
- $577.3M
- 1M return
- -3.27%
- -5.23%
- 1Y return
- -44.90%
- -66.05%
- Industry
- Real Estate
- Real Estate
- Exchange
- NYSE
- NYSE
- IPO
- 2001
- 2019
- News (4w)
- 35
- 6
- Recent ratings
- 25
- 25
Accenture plc
Accenture plc, a professional services company, provides strategy and consulting, interactive, and technology and operations services worldwide. The company also provides outsourcing services. It serves communications, media, high tech, software, and platform companies; banking, capital market, and insurance industries; and consumer goods, retail, travel services, industrial, and life science industries, as well as clients in health, public service, chemicals and natural resources, energy, and utility sectors. Accenture plc has alliance relationships with Adobe, Alibaba, Amazon Web Services, Blue Yonder, Cisco, Dell, Google, HPE, IBM RedHat, Microsoft, Oracle, Pegasystems, Salesforce, SAP, ServiceNow, VMWare, Workday, Massachusetts Institute of Technology, Institut Polytechnique de Paris, CNH Industrial, and Reactive Technologies. It has an agreement with Duke Energy Corporation for the development of a technology platform designed to measure actual baseline methane emissions from natural gas distribution systems. The company was incorporated in 2009 and is based in Dublin, Ireland.
Phreesia Inc.
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a Web-based dashboard for providers; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; appointments solution for online appointments, reminders, and referral tracking; and patient activation solution that enables providers to communicate with their patients through surveys, announcements, messaging, and health campaigns. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and PRO data for approximately 25 specialties; and life sciences solution to deliver targeted and clinically relevant marketing content to patients, as well as COVID-19 product offerings for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was founded in 2005 and is headquartered in Raleigh, North Carolina.
Latest ACN
- Chief Accounting Officer Burgum Melissa A was granted 112 units of Class A ordinary shares, increasing direct ownership by 1% to 8,579 units (SEC Form 4)
- General Counsel/Corp Secretary Unruch Joel was granted 153 units of Class A ordinary shares, increasing direct ownership by 0.55% to 28,031 units (SEC Form 4)
- Chief Leadership & HR Officer Clifford Katherine Lee was granted 98 units of Class A ordinary shares, increasing direct ownership by 2% to 6,531 units (SEC Form 4)
- CEO-The Americas Walsh John F was granted 153 units of Class A ordinary shares, increasing direct ownership by 0.60% to 25,722 units (SEC Form 4)
- Chair and CEO Sweet Julie Spellman was granted 216 units of Class A ordinary shares, increasing direct ownership by 1% to 16,235 units (SEC Form 4)
- Chief Financial Officer Park Angie Y was granted 153 units of Class A ordinary shares, increasing direct ownership by 1% to 13,118 units (SEC Form 4)
- Chief Operating Officer Hogan Catherine Kiernan was granted 119 units of Class A ordinary shares, increasing direct ownership by 0.90% to 13,321 units (SEC Form 4)
- Chief Strategy & Services Ofcr Sharma Manish was granted 102 units of Class A ordinary shares, increasing direct ownership by 2% to 5,545 units (SEC Form 4)
- Accenture to Acquire Leading Creator and Social Agency Whalar, from Whalar Group
- Accenture and the Carnegie Mellon University Software Engineering Institute Launch AI Adoption Maturity Model to Help Organizations Scale AI with Predictable Outcomes
Latest PHR
- SEC Form 10-Q filed by Phreesia Inc.
- Phreesia downgraded by Piper Sandler with a new price target
- Phreesia Announces First Quarter Fiscal 2027 Results
- Phreesia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Principal Accounting Officer Hui Yvonne sold $3,814 worth of shares (431 units at $8.85) as part of a pre-agreed trading plan and covered exercise/tax liability with 325 shares, decreasing direct ownership by 3% to 23,908 units (SEC Form 4) (for tax liability)
- Phreesia downgraded by Wells Fargo with a new price target
- Phreesia downgraded by Barclays with a new price target
- SEC Form DEFA14A filed by Phreesia Inc.
- SEC Form DEF 14A filed by Phreesia Inc.
- Phreesia Inc. filed SEC Form 8-K: Other Events